{"paper_id":"c67d99fe-47d6-4ea5-8660-3ad79c449b50","body_text":"Abstract\nKeywords: N-acetyl transferases, acetylator polymorphism, Alzheimer's disease, Parkinson's disease, diabetes mellitus, rheumatoid arthritis, autoimmune diseases, drug response, side effects\nCurrent Drug Metabolism\nTitle: Influence of Polymorphic N-Acetyltransferases on Non-Malignant Spontaneous Disorders and on Response to Drugs\nVolume: 9 Issue: 6\nAuthor(s): J. M. Ladero\nAffiliation:\nKeywords: N-acetyl transferases, acetylator polymorphism, Alzheimer's disease, Parkinson's disease, diabetes mellitus, rheumatoid arthritis, autoimmune diseases, drug response, side effects\nAbstract: Polymorphic N-acetyl transferases (NAT) 1 and 2 are involved in detoxification of xenobiotic arylamines and hydralazines. These common environmental chemicals may be related to the pathogenesis of many spontaneous disorders, mainly malignancies, but also disimmune or degenerative diseases, for which a polygenic predisposition has been suggested. Hence, polymorphic NAT genes (NAT2 has been the most studied one) may be low-penetrance risk genes for some of these disorders. Although a relation of risk may be definitely discarded for systemic lupus erythematosus (SLE), inflammatory bowel disease and endometriosis, more research is needed for rheumatoid arthritis, Parkinsons, Alzheimers, Behcets and periodontal diseases , as current results are inconclusive but suggest a possible relation with NAT2 polymorphism. In diabetes mellitus the possible relation with the rapid phenotype may be due to acquired metabolic changes and more genotyping studies are needed. NAT2 slow metabolizers are more prone to the side effects of polymorphically acetylated drugs, as is the SLE-like syndrome induced by hydralazine and procainamide, the side effects due to sulphasalazine and the skin rash secondary to many sulphonamides. Future research should be based on well-designed studies, with adequate sample sizes and homogeneous recruitment criteria, to obviate the proliferation of small studies that are time- and resource-consuming without offering definite answers.\nExport Options\nAbout this article\nCite this article as:\nLadero M. J., Influence of Polymorphic N-Acetyltransferases on Non-Malignant Spontaneous Disorders and on Response to Drugs, Current Drug Metabolism 2008; 9 (6) . https://dx.doi.org/10.2174/138920008784892038\n| DOI https://dx.doi.org/10.2174/138920008784892038 |\nPrint ISSN 1389-2002 |\n| Publisher Name Bentham Science Publishers |\nOnline ISSN 1875-5453 |\nCall for Papers in Thematic Issues\nDrug Metabolism in Cancer Immunotherapy and Next-Gen Therapeutics: Mechanistic Insights and the Impact of Co-administered Drugs\nDrug Metabolism in Cancer Immunotherapy and Next-Gen Therapeutics: Mechanistic Insights and the Impact of Co-administered Drugs\" aims to highlight the emerging insights into how metabolic processes affect the safety, efficacy, and ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) profiles and Pharmacodynamics of emerging anticancer therapies when used alone or in ...read more\nInnovative Therapeutic Approaches in Infectious Diseases\nInfectious diseases continue to challenge global health systems due to rising antimicrobial resistance, emerging pathogens, and increasing drug tolerance. This special issue aims to move beyond traditional approaches by exploring innovative pharmacological strategies for the treatment of infectious diseases. We welcome original research and reviews ranging from clinical trials and ...read more\nPharmacokinetics of Nanocarriers: Challenges, Innovations, and Translational Perspectives\nThis thematic issue will focus on the evolving field of nanocarrier-based drug delivery systems and their pharmacokinetic behavior. Understanding the ADME (Absorption, Distribution, Metabolism, and Excretion) properties of nanoparticles is crucial for optimizing therapeutic efficacy and minimizing systemic toxicity. The issue will highlight the influence of nanocarrier physicochemical properties (size, ...read more\nUnveil the Potential of Functional Framework Nucleic Acids in Theranostics\nNanomedicine demonstrates remarkable potential in disease diagnosis and treatment by precisely manipulating the physicochemical properties of materials on the nanometer scale. Its advantages as nanocarriers include high loading capacity, prolonged in vivo half-life and controllable targeted delivery. However, existing vectors (such as liposomes, polymers, and inorganic particles) still face significant ...read more\n- Author Guidelines\n- Bentham Author Support Services (BASS)\n- Graphical Abstracts\n- Fabricating and Stating False Information\n- Research Misconduct\n- Post Publication Discussions and Corrections\n- Publishing Ethics and Rectitude\n- Increase Visibility of Your Article\n- Archiving Policies\n- Peer Review Workflow\n- Order Your Article Before Print\n- Promote Your Article\n- Manuscript Transfer Facility\n- Editorial Policies\n- Allegations from Whistleblowers\n- Announcements\nRelated Articles\nCurrent Diabetes Reviews Type 2 Diabetes Mellitus and Invokana: An FDA Approved Drug\nCurrent Diabetes Reviews Cyclopentenyl Cytosine (CPEC): An Overview of its in vitro and in vivo Activity\nCurrent Cancer Drug Targets The GH/IGF-1 Axis in Chronic Heart Failure\nEndocrine, Metabolic & Immune Disorders - Drug Targets Microvascular Complications of Type 2 Diabetes Mellitus\nCurrent Vascular Pharmacology High Plasmatic Levels of Advanced Glycation End Products are Associated with Metabolic Alterations and Insulin Resistance in Preeclamptic Women\nCurrent Molecular Medicine Distinct Biomarkers for Early Diagnosis of Diabetic Nephropathy\nCurrent Diabetes Reviews An Arylidene-Thiazolidinedione Derivative, GPU-4, without PPARγ Activation, Reduces Retinal Neovascularization\nCurrent Neurovascular Research Mechanisms of Cardiovascular Changes in an Experimental Model of Syndrome X and Pharmacological Intervention on the Renin-Angiotensin- System\nCurrent Vascular Pharmacology Computational Advances in Chronic Diseases Diagnostics and Therapy - II\nCurrent Drug Targets Editorial [Hot Topic: Inhibition of the Renin-Angiotensin-Aldosterone System: How to Obtain This (Executive Guest Editors: Aldo Pende and Fabrizio Montecucco )]\nCurrent Pharmaceutical Design Metabolic Syndrome and Cognitive Decline\nCurrent Alzheimer Research Chronic Inflammation in the Pancreas and Salivary Glands - Lessons from Similarities and Differences in Pathophysiology and Treatment Modalities\nCurrent Pharmaceutical Design Artemisia Species as a New Candidate for Diabetes Therapy: A Comprehensive Review\nCurrent Molecular Medicine Platelet Function and Signaling in Diabetes Mellitus\nCurrent Vascular Pharmacology Medical Treatment of Peripheral Arterial Disease: Current Concepts and Future Options\nVascular Disease Prevention (Discontinued) A Valuable Animal Model of Spinal Cord Injury to Study Motor Dysfunctions, Comorbid Conditions, and Aging Associated Diseases\nCurrent Pharmaceutical Design Neuron-glia Interaction as a Possible Pathophysiological Mechanism of Bipolar Disorder\nCurrent Neuropharmacology Small Artery Remodeling in Obesity and Insulin Resistance\nCurrent Vascular Pharmacology Disruption of Metabolic Pathways - Perspectives for the Treatment of Cancer\nCurrent Cancer Drug Targets","source_license":"public-domain-us","license_restricted":false}